Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 6 |
| List of Tables | 5 | 2 |
| List of Figures | 7 | 2 |
| Global Anti-Hypertensives Market - Introduction | 9 | 2 |
| GBI Research Report Guidance | 10 | 1 |
| Global Anti-Hypertensives Market - Market Overview | 11 | 11 |
| Introduction | 11 | 1 |
| Revenue Forecasts for the Global Anti-Hypertensives Market | 12 | 1 |
| Revenue | 12 | 1 |
| Annual Cost of Therapy | 13 | 1 |
| Treatment Usage Patterns | 14 | 1 |
| Diseased Population | 15 | 1 |
| Treatment-Seeking Population | 16 | 1 |
| Diagnosed Population | 17 | 1 |
| Prescription Population | 18 | 1 |
| Anti-Hypertensives Market Drivers | 19 | 1 |
| Uptake of Fixed Dose Combination Therapies due to Better Efficacy in Hypertension and Pulmonary Arterial Hypertension | 19 | 1 |
| Anti-Hypertensives Market Restraints | 19 | 1 |
| Low Compliance in Hypertensive Patients | 19 | 1 |
| Patent Expiries of Major Blockbusters Including Diovan, Avapro, Blopress/Atacand, Cozaar/Hyzaar and Tracleer, Pose a Threat to Market Revenues | 19 | 1 |
| Low Treatment Seeking Behavior and Diagnosis in Pulmonary Arterial Hypertension | 20 | 1 |
| Generics Share in the Global Anti-Hypertensives Market | 21 | 1 |
| Global Anti-Hypertensives Market: Therapeutic Landscape | 22 | 26 |
| Hypertension | 22 | 1 |
| Introduction | 22 | 1 |
| Treatment Flow Algorithm for Hypertension | 23 | 1 |
| Revenue | 23 | 2 |
| Annual Cost of Therapy | 25 | 2 |
| Treatment Usage Patterns | 27 | 1 |
| Diseased Population | 28 | 1 |
| Treatment-Seeking Population | 29 | 1 |
| Diagnosed Population | 30 | 1 |
| Prescription Population | 31 | 1 |
| Market Segmentation by Geography | 32 | 3 |
| Pulmonary Arterial Hypertension (PAH) Market | 35 | 1 |
| Introduction | 35 | 2 |
| Treatment Flow Algorithm for Pulmonary Arterial Hypertension | 37 | 1 |
| Revenue | 38 | 1 |
| Annual Cost of Therapy | 39 | 1 |
| Treatment Usage Patterns | 40 | 1 |
| Diseased Population | 41 | 1 |
| Treatment-Seeking Population | 42 | 1 |
| Diagnosed Population | 43 | 1 |
| Prescription Population | 44 | 1 |
| Market Segmentation by Geography | 45 | 3 |
| Global Anti-Hypertensives Market - Geographical Landscape | 48 | 26 |
| Geographical Break-up | 48 | 3 |
| The US | 51 | 1 |
| Revenue | 51 | 1 |
| Annual Cost of Therapy | 52 | 1 |
| Treatment Usage Patterns | 53 | 1 |
| Diseased Population | 54 | 1 |
| Treatment-Seeking Population | 55 | 1 |
| Diagnosed Population | 55 | 2 |
| Prescription Population | 57 | 1 |
| Top Five Countries in Europe | 58 | 1 |
| Revenue | 58 | 1 |
| Revenue by Country | 59 | 1 |
| Annual Cost of Therapy | 60 | 2 |
| Treatment Usage Patterns | 62 | 1 |
| Diseased Population | 63 | 1 |
| Treatment-Seeking Population | 64 | 1 |
| Diagnosed Population | 65 | 1 |
| Prescription Population | 66 | 1 |
| Japan | 67 | 1 |
| Revenue | 67 | 1 |
| Annual Cost of Therapy | 68 | 1 |
| Treatment Usage Patterns | 69 | 1 |
| Diseased Population | 70 | 1 |
| Treatment-Seeking Population | 71 | 1 |
| Diagnosed Population | 72 | 1 |
| Prescription Population | 73 | 1 |
| Global Anti-Hypertensives Market - Pipeline Analysis | 74 | 16 |
| Introduction | 74 | 2 |
| Research and Development Pipeline - Hypertension | 76 | 4 |
| Research and Development Pipeline - Pulmonary Arterial Hypertension | 80 | 3 |
| Profiles of Key Late-Stage Drugs in the Anti-Hypertension Market | 83 | 1 |
| SPP635 | 83 | 1 |
| Introduction | 83 | 1 |
| Efficacy | 83 | 1 |
| Safety | 83 | 1 |
| Clinical Study Details | 83 | 1 |
| Pioglitazone | 83 | 1 |
| Introduction | 83 | 1 |
| Efficacy | 84 | 1 |
| Safety | 84 | 1 |
| Clinical Study Details | 84 | 1 |
| LCZ696 | 84 | 1 |
| Introduction | 84 | 1 |
| Efficacy | 84 | 1 |
| Safety Profile | 85 | 1 |
| Clinical Study Details | 85 | 1 |
| QT1571 (Imatinib) | 85 | 1 |
| Introduction | 85 | 1 |
| Efficacy | 85 | 1 |
| Safety | 85 | 1 |
| Clinical Study Details | 85 | 1 |
| Selexipag (NS-304, ACT-293987) | 86 | 1 |
| Introduction | 86 | 1 |
| Efficacy | 86 | 1 |
| Safety | 86 | 1 |
| Clinical Study Details | 86 | 1 |
| PS-433540 (DARA) | 86 | 1 |
| Introduction | 86 | 1 |
| Efficacy | 87 | 1 |
| Safety | 87 | 1 |
| Clinical Study Details | 87 | 1 |
| Macitentan (ACT-064992, Actelion 1) | 87 | 1 |
| Introduction | 87 | 1 |
| Efficacy | 88 | 1 |
| Safety | 88 | 1 |
| Clinical Study Details | 88 | 1 |
| Riociguat (BAY63-2521) | 88 | 1 |
| Introduction | 88 | 1 |
| Efficacy | 88 | 1 |
| Safety | 88 | 1 |
| Clinical Study Details | 88 | 2 |
| Global Anti-Hypertensives Market - Competitive Landscape | 90 | 12 |
| Market Share Analysis | 90 | 1 |
| Competitive Profiling | 91 | 1 |
| Novartis | 91 | 1 |
| Product Portfolio | 91 | 1 |
| SWOT Analysis | 92 | 1 |
| Merck | 92 | 1 |
| Product Portfolio | 92 | 1 |
| SWOT Analysis | 93 | 1 |
| Daiichi Sankyo | 93 | 1 |
| Product Portfolio | 93 | 1 |
| SWOT Analysis | 94 | 1 |
| Sanofi | 94 | 1 |
| Product Portfolio | 94 | 1 |
| SWOT Analysis | 95 | 1 |
| AstraZeneca | 95 | 1 |
| Product Portfolio | 96 | 1 |
| SWOT Analysis | 96 | 1 |
| United Therapeutics | 97 | 1 |
| Product Portfolio | 97 | 1 |
| SWOT Analysis | 98 | 1 |
| Actelion | 98 | 1 |
| Product Portfolio | 98 | 2 |
| SWOT Analysis | 100 | 1 |
| Pfizer | 100 | 1 |
| Product Portfolio | 100 | 1 |
| SWOT Analysis | 101 | 1 |
| Global Anti-Hypertensives Market - Strategic Consolidations | 102 | 10 |
| Overview | 102 | 1 |
| Deals by Type | 102 | 1 |
| M&A Deals by Indication | 103 | 1 |
| M&A Deals by Year | 103 | 1 |
| M&A Deals by Geography | 104 | 1 |
| Summary of Major M&A Deals | 105 | 1 |
| Eli Lilly Acquires ICOS in January 2007 | 105 | 1 |
| Abbott Laboratories Acquires Solvay Pharmaceuticals in February 2010 | 106 | 1 |
| Endo Pharmaceuticals to Acquire Qualitest Pharmaceuticals in 2010 | 106 | 1 |
| Jubilant Organosys Acquires Trinity Laboratories and Trigen Laboratories in 2007 | 106 | 1 |
| Daiichi Sankyo Acquires Plexxikon in April 2011 | 106 | 1 |
| R&D Licensing Agreements | 107 | 1 |
| Licensing Agreements by Indication | 107 | 1 |
| Licensing Agreements by Phase | 108 | 1 |
| Licensing Agreements by Geography | 108 | 1 |
| Licensing Agreements for Drugs in Phase II and Phase III Stage | 109 | 1 |
| Aviptadil | 109 | 1 |
| NS304 | 109 | 1 |
| EG-PO42 | 110 | 1 |
| Macitentan | 110 | 1 |
| Licensing Agreements for Approved Drugs | 110 | 1 |
| Diovan | 111 | 1 |
| Olmetec | 111 | 1 |
| Futuran | 111 | 1 |
| Letairis | 111 | 1 |
| Amosartan | 111 | 1 |
| Global Anti-Hypertensives Market - Appendix | 112 | 8 |
| Market Definitions | 112 | 1 |
| Abbreviations | 112 | 2 |
| Research Methodology | 114 | 5 |
| Coverage | 114 | 1 |
| Secondary Research | 114 | 1 |
| Primary Research | 114 | 1 |
| Therapeutic Landscape | 115 | 1 |
| Epidemiology-Based Forecasting | 115 | 1 |
| Market Size by Geography | 116 | 2 |
| Geographical Landscape | 118 | 1 |
| Pipeline Analysis | 118 | 1 |
| Competitive Landscape | 118 | 1 |
| Expert Panel Validation | 118 | 1 |
| Contact Us | 118 | 1 |
| Disclaimer | 118 | 1 |
| Sources | 119 | 1 |